Chiral Quest (Suzhou) Co., Ltd. – Trademark Portfolio
Entity Type: 99
Chiral Quest (Suzhou) Co., Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 1 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include CHIRAL CQ QUEST.
Unit E593, 5th Floor, Le Cheng Plaza,
No. 218 Sangtian Street, China (Jiangsu)Pilot Free Trade Zone 215000 Suzhou Area
Showing of trademarks Trademarks
Trademark Classifications
Chiral Quest (Suzhou) Co., Ltd.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Chiral Quest (Suzhou) Co., Ltd. have?
Chiral Quest (Suzhou) Co., Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.
What trademark classes does Chiral Quest (Suzhou) Co., Ltd. file in?
Chiral Quest (Suzhou) Co., Ltd. files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are Chiral Quest (Suzhou) Co., Ltd.'s most well-known trademarks?
Chiral Quest (Suzhou) Co., Ltd.'s registered trademark portfolio includes well-known marks such as CHIRAL CQ QUEST. These are among 1 currently registered trademark in the portfolio.
What is Chiral Quest (Suzhou) Co., Ltd.'s trademark registration success rate?
Chiral Quest (Suzhou) Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.